Table 1.

Correlation Between APOB mRNA Expression/Methylation and Clinicopathologic Features of 532 Patients with LGG in TCGA Database

Clinical Features		APOB Expression		P value	APOB Methylation		P value
		Low	High		Low	High
Age	≤50	196	178	0.066	172	202	0.004
	>50	69	89		94	64
Gender	Female	117	124	0.596	127	114	0.258
	Male	148	143		139	152
Race	White/American	243	248	0.425	242	249	0.094
	Black/Africa american	9	13		16	6
	Asian	6	3		5	4
Histological Type	Astrocytoma	100	97	0.507	126	71	<0.001
	Oligodendroglioma	104	97		81	120
	Mixed glioma	61	73		59	75
Family history of cancer	Yes	59	79	0.155	73	65	0.433
	No	112	110		108	114
IDH1-mutation	Mutant	68	23	0.001	26	65	<0.001
	Wildtype	15	19		27	7
Laterality	Left	137	121		131	127
	Midline	5	2		3	4
	Right	119	143		129	133
WHO grade	II	129	132	0.828	108	153	<0.001
	III	136	134		157	113
Cancer status	With tumor	113	140	0.048	134	119	0.011
	Tumor free	93	78		69	102
KPS	≤80	10	19	0.448	15	14	0.649
	>80	17	22		18	21
Sample type	pLGG	253	261	0.146	253	261	0.055
	rLGG	12	6		13	5
Radiotherapy	Yes	138	149	0.604	159	128	<0.001
	No	89	87		66	110
OS	Alive	214	178	<0.001	173	219	<0.001
	Dead	48	88		92	44
MTD	≤2cm	71	131	0.087	93	109	0.153
	>2cm	3	16		12	7
Seizure history	Yes	150	164	0.512	161	153	0.652
	No	93	90		88	95
APOB mRNA expression	Low	-	-	-	97	168	<0.001
	High	-	-		169	98
APOB Methylation	Low	97	169	<0.001	-	-	-
	High	168	98		-	-	-

Abbreviations: KPS, Kamofsky performance status; WHO, World health organization; OS, overall survival; MTD, maximum tumor diameter; pLGG, primary low-grade glioma; rLGG, recurrent low-grade glioma.